Starpax Biopharma Inc. has officially launched a Regulation A capital raise to finance its clinical trials on humans. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Starpax Biopharma Inc. has officially launched a Regulation A capital raise to finance its clinical trials on humans. The technology is conceived to tackle a major resistance problem for cancer treatments and bring hope to patients and their families worldwide.
(By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time)
Read on to learn more about Starpax’s revolutionary technology and the opportunity to invest.
Studies have shown that roughly 90% of the volume of a tumor receives little to no medication when it comes to current systemic cancer treatments.
Starpax Biopharma is set to address the US$901 billion solid tumor treatment market by creating the cancer treatment of the future with its never-before-seen Precision 3D Guidance Therapy, including Starpax Living Magnetodronesô and PolarTrak® technology.
Reduced risk of failure and shortened expected FDA reviews. According to the FDA, 97% of clinical trials with new drugs fail, posing a substantial financial risk to investors. Since Starpax Technology is conceived to use anti-cancer molecules that are already FDA-approved and have been used in humans for years, investors face a lower risk of failure. Additionally, Starpax addresses six of the most common cancers simultaneously, increasing the number of patients available for clinical trials compared to single rare drug trials. Starpax also meets the criteria of the FDA Fast Track Program and Health Canada accelerated review standards. Both factors will speed up Starpax’s trials and approvals.
Living Magnetodrones, Artificial Intelligence, and Patented Magnetic Fields to treat cancer. With conventional systemic treatments, 90% of the tumor receives little or no drug due to malfunctioning and collapsed blood vessels in tumors. Starpax Living Magnetodrones are conceived to distribute drugs into the tumor without using blood vessels and can penetrate and accumulate in hypoxic zones. Hypoxic zones are key to treating cancer since that’s where the cancer stem cells are located, but they can’t be reached by current conventional drugs or immune cells. The PolarTrak device in which the patient is placed is conceived to use its patented magnetic fields, controlled by Starpax’s AI technology, to trap the Magnetodrones transporting drugs inside the tumor and force them to spread throughout. Preclinical tests have resulted in a 100% remission rate in extremely aggressive tumors without any toxicity observed.
Business model built to scale rapidly. Starpax has engaged specialized firms in the U.S. to find the best commercial solutions to reach patients as fast as possible. The business model involves starting the deployment of 25 Starpax Cancer Treatment Centers (of the 580 needed in the U.S.) within seven years, with a forecasted EBITDA of US$348 million in Year 2 and US$12 billion in Year 7 upon FDA approval.
Starpax’s technology is set to revolutionize cancer care and improve the lives of patients worldwide. Be part of a mission to create a world where cancer treatment is more effective, safe and accessible.
(By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time)
The Starpax Team
Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.
This message is a paid advertisement sent on behalf of Starpax, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
